Bleomycin A5 plus dexamethasone for control of growth in infantile parotid hemangiomas.
OBJECTIVE
The purpose of this study was to evaluate the efficacy of bleomycin A5 (pingyangmycin) plus dexamethasone for control of growth in infantile parotid hemangiomas.


METHODS
We reviewed and analyzed the data of 31 cases undergoing therapy of intralesional injection with small-dosage and low-concentration bleomycin A5 plus dexamethasone between June 2004 and October 2007. Clinical manifestations, image characteristics, and therapeutic outcomes were reviewed. The therapeutic outcomes were evaluated by physical examination, photographs, and Doppler ultrasonography. The follow-up was from 6 months to 3 years after ending treatment.


RESULTS
Twenty-five patients (80.6%) had a response rate greater than 90% reduction in tumor size. Three patients (9.7%) had a response rate between 75% and 90% reduction in tumor size. Another 3 patients (9.7%) had a response rate between 50% and 75% reduction in size. No patients had less than a 50% response rate. There was no recurrence, allergic reaction, pulmonary fibrosis, fever, or other complication during or after the course of treatment.


CONCLUSIONS
The controlling therapy with small-dosage and low-concentration bleomycin A5 plus dexamethasone can treat the parotid hemangiomas of infants effectively, especially for lesions in the early phase and proliferative phase. Early control and long-term observation are the key aspects of treatment.
Yang
Yaowu
Y
Department of Oral and Maxillofacial Surgery, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi, China. yangyaowu_1@sina.com
Sun
Moyi
M
Cheng
Xiaobing
X
Hu
Xiaoguang
X
Zhang
Pu
P
Ma
Qin
Q
Li
Jianhu
J
Tian
Lei
L
Lei
Delin
D
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003287:Contrast Media; D003907:Dexamethasone / Q000008:administration & dosage*; D005260:Female; D005500:Follow-Up Studies; D019786:Gadolinium DTPA; D006391:Hemangioma / Q000188:drug therapy*; D006801:Humans; D007223:Infant; D015552:Injections, Intralesional; D008279:Magnetic Resonance Imaging; D008297:Male; D010307:Parotid Neoplasms / Q000188:drug therapy*; D010781:Photography; D010808:Physical Examination; D012074:Remission Induction; D016896:Treatment Outcome; D018608:Ultrasonography, Doppler
D000903:Antibiotics, Antineoplastic; D018931:Antineoplastic Agents, Hormonal; D003287:Contrast Media; D001761:Bleomycin; C025703:bleomycetin; D003907:Dexamethasone; D019786:Gadolinium DTPA